Request Your Free White Paper Now:

"Accelerate Clinical Trials with Methylation-Based ctDNA Detection"

Learn from biopharma industry leaders about how methylation-based ctDNA detection for precise MRD and response monitoring can accelerate your clinical trials.

As oncology trials grow more complex, biopharma leaders are turning to methylation-based circulating tumor DNA (ctDNA) testing to gain earlier, more precise insights into patient response and residual disease. Access this valuable whitepaper today to explore how to leverage this approach to accelerate development timelines, improve data confidence, and optimize trial design.

You’ll learn more about methylation-based ctDNA testing and how to:

• Identify eligible patients more accurately to improve enrollment efficiency
• Drive earlier signals of therapeutic response, supporting adaptive trial strategies and faster decisions
• Deliver sensitive, non-invasive monitoring of minimal residual disease across the patient journey
• Reduce reliance on traditional imaging endpoints, helping to streamline operations and shorten study duration
• And more

This resource provides a forward-looking perspective on how to advance precision oncology and shape the next generation of clinical trials. Download now!

Offered Free by: Guardant Health
See All Resources from: Guardant Health